Inactive Instrument

All News Tenax Therapeutics Inc Nasdaq

Equities

US88032L1008

All News

Unlock all the news: Be the first to know and act before the market!

Tenax Therapeutics: Q1 Earnings Snapshot	05-14	AQ
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update	05-14	AQ
Tenax Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	04-30	AQ
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”	04-09	AQ
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results	03-28	AQ
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Tenax Therapeutics to Present at the 36th Annual Roth Conference	03-12	AQ
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024	02-29	AQ
Tenax Therapeutics Secures Global Rights for Levosimendan	02-20	MT
Tenax Therapeutics, Inc. and Orion Corporation Enters into an Amendment to Certain License Agreement	02-20	CI
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan	02-20	AQ
Top Midday Decliners	02-08	MT
Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected	02-08	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Investors Await Economic Data	02-08	MT
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering	02-08	AQ
US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data	02-08	MT
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	02-07	AQ
Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients	02-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Tenax Therapeutics Inc Nasdaq

Equities

US88032L1008

All News

Filters